Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge

Inclusion Criteria: 1. The performance status of Eastern Cooperative Oncology Group (ECOG) must be 0-1 2. The diagnosis of primary hepatocellular carcinoma must be in line with the American Society for the study of liver diseases (AASLD) diagnostic criteria for hepatocellular carcinoma (HCC) 3. Child-Pugh score A or B; 4. Aged from 18 to 75 years; 5. Subjects voluntarily join the study, and signe informed consent; 6. No anti-tumor therapy was received； 7. Meet the following 4 characteristics: A. primary tumor diameter more than or equal to 10cm; B. no more than 3 HCC foci, and the maximum diameter is less than or equal to 5cm; C. with IIa, I or no portal vein tumor thrombus (Cheng's Classification)；D. the tumor could not be surgically removed 8. No extrahepatic metastases Exclusion Criteria: 1. Abnormal coagulation function: PLT \< 40×109/L, PTA \< 40%; 2. Patients have the past history of liver cancer treatment, such as transplantation, resection, radiotherapy, chemotherapy and so on; 3. Patients participated in clinical trials of equipment or drugs (signed informed consent) within 4 weeks; 4. Patients accompany by ascites, hepatic encephalopathy and esophageal and gastric varices bleeding; 5. Any serious accompanying disease, which is expected to have an unknown, impact on the prognosis, include heart disease, inadequately controlled diabetes and psychiatric disorders; 6. Patients accompanied with other tumors or past medical history of malignancy; 7. Pregnant or lactating patients, all patients participating in this trial must adopt appropriate birth control measures during treatment; 8. Allergic to adriamycin chemotherapy drugs，contrast agent and lipiodol; 9. Patients have poor compliance.